Combination therapy with or without fecal transplant for nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a new combination of chemotherapy, immunotherapy, and possibly a fecal transplant for people with nasopharyngeal cancer that has spread to a few places in the body. It aims to see if adding a fecal transplant helps the treatment work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have nasopharyngeal cancer that has spread to 3 or fewer organs and 5 or fewer spots in the body.
- You have not had chemotherapy for this cancer before, except more than 6 months ago.
- You are able to take care of yourself (performance status score of at least 70, or at least 50 if due to the tumor).
- You have at least one tumor that can be measured and has not been treated with radiation.
- You do not have an active autoimmune disease or a history of autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding a PD-1 inhibitor to standard chemotherapy (TPF) before the main treatment can shrink advanced nasopharyngeal cancer that has spread beyond the nasopharynx. It is for people who have not had any prior treatment for their cancer.
This Phase 3 trial compares different chemotherapy drugs given along with radiation therapy for people with locally advanced nasopharyngeal cancer. It aims to find which drug approach works better and is safer for this stage of disease.
This trial tests whether adding chemotherapy to a combination of immunotherapy and radiation is more effective than immunotherapy and radiation alone for advanced nasopharyngeal cancer. It is for people whose cancer has not spread to distant organs.
This trial tests whether adding a medicine called TNF to standard chemotherapy and radiation helps people with locally advanced nasopharyngeal cancer. It also compares outcomes between giving TNF and not giving TNF, to see which approach works better and is safe.
This trial is for people with high-risk, newly diagnosed stage T3N1M0 nasopharyngeal cancer. It compares whether you need chemotherapy first (before radiation and chemotherapy together) to improve outcomes.
This trial tests a combination of the immunotherapy drug tislelizumab with chemotherapy for people whose nasopharyngeal cancer has spread to the bones. It may be an option if you have not had prior treatment for advanced disease.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.